References
- Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ, Mulder E. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 1993; 23: 213–23
- Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139–46
- Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn J Clin Oncol 2000; 30: 21–6
- Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839–44
- Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750–7
- Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: 898–903
- Kaku H, Tsushima T, Nasu Y, Kumon H. Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer. Nippon Rinsho 2002;11:182–7 (in Japanese).
- Johansen TE, Ogreid P, Kjellevold K, Blom P. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate. Br J Urol 1990; 65: 376–8
- Kisman OK, de Voogt HJ, Baak JA. Reversibility of the effect of LHRH agonists and other antiandrogenic hormones on the testis: a histomorphometric study. Eur Urol 1990; 18: 299–301
- Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714–20
- Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999; 54: 694–9
- Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891–4